论文信息 - Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. - 字舞流文

Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.

A. Hauschild | S. Arron | C. Rudin | J. Hainsworth | L. Dirix | P. Friedlander | K. Lewis | J. Hou | A. Sekulic | A. Chang | Ellen S. Marmur | M. Migden | H. Yue | J. Solomon | S. Yoo

[1] Frank Cirrone,et al. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma. , 2012, Clinical therapeutics.

[2] J. Lear. Oral hedgehog-pathway inhibitors for basal-cell carcinoma. , 2012, The New England journal of medicine.

[3] Aleksandar Sekulic,et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.

[4] W. Matsui,et al. Hedgehog pathway as a drug target: Smoothened inhibitors in development , 2012, OncoTargets and therapy.

[5] M. Leverkus,et al. Basal Cell Carcinoma: From the Molecular Understanding of the Pathogenesis to Targeted Therapy of Progressive Disease , 2010, Journal of skin cancer.

[6] J. Low,et al. The Role of the Hedgehog Signaling Pathway in the Development of Basal Cell Carcinoma and Opportunities for Treatment , 2010, Clinical Cancer Research.

[7] Sophie Couvé-Privat,et al. Sonic hedgehog signaling in basal cell carcinomas. , 2005, Cancer letters.

[8] M. Wolter,et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. , 1998, Cancer research.

[9] Q. Gu,et al. Activating Smoothened mutations in sporadic basal-cell carcinoma , 1998, Nature.